We are very excited to announce a new drug discovery project in our lab aimed at accelerating the development of innovative therapies for Parkinson’s disease, which runs in collaboration with CD3 at KU Leuven, SandboxAQ, and The Michael J. Fox Foundation.

By harnessing cutting-edge AI technology at SandboxAQ and our team’s expertise in lysosomal transporters ATP10B and ATP13A2, we’re working to identify novel drug compounds with the aim to make a meaningful impact for those living with this complex condition.

Together, we’re committed to pushing the boundaries of what’s possible in Parkinson’s disease drug discovery research.